Literature DB >> 15802495

Evidence for ototopical glucocorticoid-induced decrease in hypothalamic-pituitary-adrenal axis response and liver function.

Getu Abraham1, Jutta Gottschalk, Fritz Rupert Ungemach.   

Abstract

To clarify whether ototopical glucocorticoid treatment is associated with impaired hypothalamic-pituitary-adrenal axis (HPA) activity and altered hepatic metabolism, one commercially available dexamethasone-containing ointment was tested. At present, very little is known about the effects of ototopical glucocorticoid treatment on HPA and liver function. Ten beagle dogs received two daily therapeutic doses of dexamethasone (0.6 mg/ear) in the outer auditory canal for 21 d in a single-blind, placebo-controlled study. Resting cortisol concentrations were assessed before, during, and after treatment using an RIA system. Adrenal function and HPA feedback sensitivity were measured by a standard dose (250 microg) ACTH stimulation test. Serum biochemical and hematological parameters were measured, whether ototopical glucocorticoids affect hepatic function was studied, and blood cell counts were made. Ototopical dexamethasone treatment induced a marked suppression (to about 100%) of resting plasma cortisol concentrations below the placebo effect (P < 0.0001) within the first 11 d, and these remained reduced during the entire treatment period up to d 19. As well, an ACTH stimulation test found a markedly reduced rise in plasma cortisol concentrations (P = 0.0004). Concomitantly, significant increases in serum activities of alkaline phosphatase, gamma-glutamyl transferase, alanine transaminase, and aspartate transaminase were detected. Moreover, we found a significant reduction in differential leukocyte counts of eosinophils and lymphocytes, whereas neutrophils increased. Although cortisol levels and hematological parameters returned to baseline 7 d after treatment cessation, liver enzyme activities remained elevated. In conclusion, these findings suggest that after ototopical application, dexamethasone is sufficiently absorbed from the auditory canal to suppress HPA function as well as to alter metabolic and hemopoietic profiles. Thus, in long-term treatment of otitis externa or media, the systemic adverse suppression of HPA has to be considered in relation to stress exposure, whereas changes in serum enzyme activities may not be interpreted as hepathopathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15802495     DOI: 10.1210/en.2005-0080

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Consequences of systemic absorption of topical glucocorticoids.

Authors:  Lynnette K Nieman
Journal:  J Am Acad Dermatol       Date:  2011-07       Impact factor: 11.527

2.  Use of topical glucocorticoids in veterinary dermatology.

Authors:  Frédéric Sauvé
Journal:  Can Vet J       Date:  2019-07       Impact factor: 1.008

Review 3.  The unresolved riddle of glucocorticoid withdrawal.

Authors:  F Guerrero Pérez; A P Marengo; C Villabona Artero
Journal:  J Endocrinol Invest       Date:  2017-05-20       Impact factor: 4.256

4.  Do topical ophthalmic corticosteroids suppress the hypothalmic-pituitary-adrenal axis in post-penetrating keratoplasty patients?

Authors:  S S Sandhu; J M Smith; M Doherty; A James; F C Figueiredo
Journal:  Eye (Lond)       Date:  2012-02-17       Impact factor: 3.775

Review 5.  Corticosteroid therapy for hearing and balance disorders.

Authors:  Dennis R Trune; Barbara Canlon
Journal:  Anat Rec (Hoboken)       Date:  2012-10-08       Impact factor: 2.064

6.  Evaluation of Basal Serum or Plasma Cortisol Concentrations for the Diagnosis of Hypoadrenocorticism in Dogs.

Authors:  A J Gold; D K Langlois; K R Refsal
Journal:  J Vet Intern Med       Date:  2016-10-07       Impact factor: 3.333

7.  Pharmacokinetic evaluation of a transdermal anastrozole-in-adhesive formulation.

Authors:  Ralf Regenthal; Margarita Voskanian; Frank Baumann; Jens Teichert; Christian Brätter; Achim Aigner; Getu Abraham
Journal:  Drug Des Devel Ther       Date:  2018-11-01       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.